{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {
    "id": "vLE658_kPyPg"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/yijie/anaconda3/lib/python3.8/site-packages/pandas/core/computation/expressions.py:20: UserWarning: Pandas requires version '2.7.3' or newer of 'numexpr' (version '2.7.1' currently installed).\n",
      "  from pandas.core.computation.check import NUMEXPR_INSTALLED\n"
     ]
    }
   ],
   "source": [
    "import sys\n",
    "import datetime as dt\n",
    "import pandas as pd\n",
    "pd.set_option(\"display.max_rows\",500)\n",
    "pd.set_option(\"display.max_columns\",500)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "4lB-YZMgQRYA"
   },
   "source": [
    "# Bayer NLP task - Baseline NGRAM evaluation\n",
    "This notebook follows previous EDA notebook, working to evaluate the utility of NGRAM approaches for baseline LGBM model.\n",
    "This is done prior to moving one to alternative models\n",
    "(c) Yijie Xu"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "GtbIgIfyQT4-",
    "outputId": "632d7ea5-131e-4e0f-e6ca-bdf911dd99c0"
   },
   "outputs": [],
   "source": [
    "sys.path.insert(0, '..') # Set root directory\n",
    "sys.path.insert(0, '/home/yijie/Documents/Bayer/BayerNLP/scripts')# Set root directory"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['/home/yijie/Documents/Bayer/BayerNLP/scripts',\n",
       " '..',\n",
       " '/home/yijie/Documents/Bayer/BayerNLP/notebooks',\n",
       " '/home/yijie/anaconda3/lib/python38.zip',\n",
       " '/home/yijie/anaconda3/lib/python3.8',\n",
       " '/home/yijie/anaconda3/lib/python3.8/lib-dynload',\n",
       " '',\n",
       " '/home/yijie/anaconda3/lib/python3.8/site-packages']"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sys.path"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "id": "YydgBX99Qfok"
   },
   "outputs": [],
   "source": [
    "data =pd.read_csv(\"../data/sentences_with_sentiment.csv\",sep=\",\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 1000
    },
    "id": "Qvr-5iHYRs57",
    "outputId": "48f74051-52e9-4666-f604-2a639fefbd88"
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ID</th>\n",
       "      <th>Sentence</th>\n",
       "      <th>Positive</th>\n",
       "      <th>Negative</th>\n",
       "      <th>Neutral</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>The results in 2nd line treatment show an ORR ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>The long duration of response and high durable...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>The median OS time in the updated results exce...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Therefore, the clinical benefit in 2nd line tr...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>The data provided in 1st line, although prelim...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>6</td>\n",
       "      <td>Taking into account the intrinsic limitation o...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>7</td>\n",
       "      <td>This medicinal product has been authorised und...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>8</td>\n",
       "      <td>This means that further evidence on this medic...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>9</td>\n",
       "      <td>The European Medicines Agency will review new ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>10</td>\n",
       "      <td>The CHMP considers the following measures nece...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>11</td>\n",
       "      <td>In order to confirm the efficacy for chemother...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>12</td>\n",
       "      <td>The final results of the study should be submi...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>13</td>\n",
       "      <td>The CHMP considers that additional supportive ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>14</td>\n",
       "      <td>• PASS: German real-world cohort study should ...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>15</td>\n",
       "      <td>The safety data collected at an earlier data c...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>16</td>\n",
       "      <td>No major concerns have been identified in the ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>17</td>\n",
       "      <td>The safety of avelumab in the proposed indicat...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>18</td>\n",
       "      <td>The safety risks associated with immune relate...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>19</td>\n",
       "      <td>The CHMP considers the following measures nece...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>20</td>\n",
       "      <td>• PASS: German real-world cohort study should ...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>21</td>\n",
       "      <td>Biosimilarity of CT-P10 and MabThera is consid...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>22</td>\n",
       "      <td>In the pivotal RA trial, efficacy results in t...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>23</td>\n",
       "      <td>In addition, PK data discussed support the ext...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>24</td>\n",
       "      <td>The objectives of study CT-P10 3.3 were to dem...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>25</td>\n",
       "      <td>The overall safety profile of CT-P10 appeared ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>26</td>\n",
       "      <td>Therefore, the available safety data are consi...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>27</td>\n",
       "      <td>Most common reported events were infections, i...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>28</td>\n",
       "      <td>The frequencies and nature of the adverse even...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>29</td>\n",
       "      <td>Although dataset of AFL patients has been upda...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>30</td>\n",
       "      <td>Additional safety data from maintenance study ...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>31</td>\n",
       "      <td>The planned extension studies CT-P10 3.2 (RA) ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>32</td>\n",
       "      <td>A summary of the literature with regard to cli...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>33</td>\n",
       "      <td>This is in accordance with the relevant guidel...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>34</td>\n",
       "      <td>The superiority to placebo was demonstrated fo...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>35</td>\n",
       "      <td>No significant additional benefit was observed...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>36</td>\n",
       "      <td>Therefore, the CHMP endorsed the proposed dose...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>37</td>\n",
       "      <td>Based on the presented and available data, dup...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>38</td>\n",
       "      <td>With regard to TEAE profile, no meaningful qua...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>39</td>\n",
       "      <td>As questions still remain on the long term saf...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>40</td>\n",
       "      <td>The applicant provided six pivotal studies to ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>41</td>\n",
       "      <td>Only 3 pivotal randomized double-blind multice...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>42</td>\n",
       "      <td>Based on the primary meta-analysis conducted b...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>43</td>\n",
       "      <td>This benefit difference (PPS versus placebo) r...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>44</td>\n",
       "      <td>Indeed, this benefit difference was mainly dri...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>45</td>\n",
       "      <td>Furthermore according to the meta-analysis of ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>46</td>\n",
       "      <td>Overall, the safety profile of PPS is not cons...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>47</td>\n",
       "      <td>Due to the heparin-like structure of PPS, a we...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>48</td>\n",
       "      <td>This risk is adequately addressed in various s...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>49</td>\n",
       "      <td>Based on the presented bioequivalence study th...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>50</td>\n",
       "      <td>The application contains an adequate review of...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>50</th>\n",
       "      <td>51</td>\n",
       "      <td>A biowaiver for the 20 mg strength is consider...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51</th>\n",
       "      <td>52</td>\n",
       "      <td>Based on the presented bioequivalence study Gr...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>52</th>\n",
       "      <td>53</td>\n",
       "      <td>The results of study 084-09 with 100mg formula...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>53</th>\n",
       "      <td>54</td>\n",
       "      <td>The results presented on efficacy support the ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>54</th>\n",
       "      <td>55</td>\n",
       "      <td>The number of subjects is sufficient for compa...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55</th>\n",
       "      <td>56</td>\n",
       "      <td>Broadly, the number, severity and type of TEAE...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>56</th>\n",
       "      <td>57</td>\n",
       "      <td>The frequency of related AEs, severity of AEs ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>57</th>\n",
       "      <td>58</td>\n",
       "      <td>More detailed data on injection site reactions...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>58</th>\n",
       "      <td>59</td>\n",
       "      <td>The submitted additional analyses further supp...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>59</th>\n",
       "      <td>60</td>\n",
       "      <td>With regard to immunogenicity, the incidence a...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60</th>\n",
       "      <td>61</td>\n",
       "      <td>No worsening of the immunogenicity profile was...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>61</th>\n",
       "      <td>62</td>\n",
       "      <td>There was no clinical efficacy study performed...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>62</th>\n",
       "      <td>63</td>\n",
       "      <td>In light of established biosimilarity on quali...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>63</th>\n",
       "      <td>64</td>\n",
       "      <td>For the purpose of the clinical biosimilarity ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>64</th>\n",
       "      <td>65</td>\n",
       "      <td>1).Nevertheless, the applicant has conducted t...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65</th>\n",
       "      <td>66</td>\n",
       "      <td>This data is considered supportive in establis...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>66</th>\n",
       "      <td>67</td>\n",
       "      <td>Both studies, demonstrated that SAR342434 is n...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>67</th>\n",
       "      <td>68</td>\n",
       "      <td>The 12-month results of study EFC12619 further...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>68</th>\n",
       "      <td>69</td>\n",
       "      <td>The size of the safety database and duration o...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>69</th>\n",
       "      <td>70</td>\n",
       "      <td>Safety and tolerability of Insulin lispro Sano...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>70</th>\n",
       "      <td>71</td>\n",
       "      <td>With regard to immunogenicity, the differences...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>71</th>\n",
       "      <td>72</td>\n",
       "      <td>Treatment-emergent AIA did not affect efficacy...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>72</th>\n",
       "      <td>73</td>\n",
       "      <td>In conclusion, the safety profile of Insulin l...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>73</th>\n",
       "      <td>74</td>\n",
       "      <td>The bioequivalence of the applied product Ivab...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>74</th>\n",
       "      <td>75</td>\n",
       "      <td>The study has been performed under fed conditi...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>75</th>\n",
       "      <td>76</td>\n",
       "      <td>The sample size was calculated to provide adeq...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>76</th>\n",
       "      <td>77</td>\n",
       "      <td>The statistical methodology used in the studie...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>77</th>\n",
       "      <td>78</td>\n",
       "      <td>In accordance with the study protocol the stud...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>78</th>\n",
       "      <td>79</td>\n",
       "      <td>The bioequivalence study appears to have been ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>79</th>\n",
       "      <td>80</td>\n",
       "      <td>An acceptable justification for a biowaiver of...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>80</th>\n",
       "      <td>81</td>\n",
       "      <td>to the EMA Guideline on the Investigation of B...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>81</th>\n",
       "      <td>82</td>\n",
       "      <td>The efficacy data of the two phase 3 placebo-c...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>82</th>\n",
       "      <td>83</td>\n",
       "      <td>The active-comparator study demonstrated the e...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83</th>\n",
       "      <td>84</td>\n",
       "      <td>Overall, data of the submitted studies are con...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>84</th>\n",
       "      <td>85</td>\n",
       "      <td>The safety observation is based on a total of ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>85</th>\n",
       "      <td>86</td>\n",
       "      <td>Sarilumab is associated with infections (inclu...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>87</td>\n",
       "      <td>No new safety concerns were identified during ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>87</th>\n",
       "      <td>88</td>\n",
       "      <td>The efficacy of the combination of lenvatinib ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>88</th>\n",
       "      <td>89</td>\n",
       "      <td>Lenvatinib/everolimus combination therapy demo...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>89</th>\n",
       "      <td>90</td>\n",
       "      <td>Additional sensitivity analyses performed conf...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>90</th>\n",
       "      <td>91</td>\n",
       "      <td>Furthermore, encouraging signs of a prolonged ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>91</th>\n",
       "      <td>92</td>\n",
       "      <td>A similar trend towards prolonged OS was also ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>93</td>\n",
       "      <td>The overall safety profile of lenvatinib-evero...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>93</th>\n",
       "      <td>94</td>\n",
       "      <td>The reported toxicity was in general predictab...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>95</td>\n",
       "      <td>No new safety signal has been reported.</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>96</td>\n",
       "      <td>However, most of these adverse events were wel...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>97</td>\n",
       "      <td>However, precaution is warranted given a small...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>98</td>\n",
       "      <td>Although toxicity appears to be manageable wit...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>98</th>\n",
       "      <td>99</td>\n",
       "      <td>Poor tolerability of the combination is manife...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>99</th>\n",
       "      <td>100</td>\n",
       "      <td>Therefore, further studies need to be conducte...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>100</th>\n",
       "      <td>101</td>\n",
       "      <td>The CHMP considers the following measures nece...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>101</th>\n",
       "      <td>102</td>\n",
       "      <td>Study 307 is requested to further characterise...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>102</th>\n",
       "      <td>103</td>\n",
       "      <td>Study 221 will continue to characterize safety...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>103</th>\n",
       "      <td>104</td>\n",
       "      <td>Study 010 will assess in vitro lenvatinib prot...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>104</th>\n",
       "      <td>105</td>\n",
       "      <td>Studies requested for Lenvima will also provid...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>105</th>\n",
       "      <td>106</td>\n",
       "      <td>Based on the available data, the CHMP consider...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>106</th>\n",
       "      <td>107</td>\n",
       "      <td>Therefore the absence of a bioequivalence stud...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>107</th>\n",
       "      <td>108</td>\n",
       "      <td>Overall, the available clinical efficacy data ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>108</th>\n",
       "      <td>109</td>\n",
       "      <td>Results from the pivotal study CLARITY showed ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>109</th>\n",
       "      <td>110</td>\n",
       "      <td>Subgroup analyses suggested a larger effect si...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>110</th>\n",
       "      <td>111</td>\n",
       "      <td>Furthermore, data in SPMS patients with superi...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>111</th>\n",
       "      <td>112</td>\n",
       "      <td>Based on these data and since relapses in both...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>112</th>\n",
       "      <td>113</td>\n",
       "      <td>The data furthermore support the use of a cumu...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>113</th>\n",
       "      <td>114</td>\n",
       "      <td>Maintenance of the treatment effect in year 3 ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>114</th>\n",
       "      <td>115</td>\n",
       "      <td>No clinically relevant added benefit of additi...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>115</th>\n",
       "      <td>116</td>\n",
       "      <td>Overall, the CHMP was of the view that the ava...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>116</th>\n",
       "      <td>117</td>\n",
       "      <td>The main safety issues were related to the ris...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>117</th>\n",
       "      <td>118</td>\n",
       "      <td>For the latter, uncertainties due to the obser...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>118</th>\n",
       "      <td>119</td>\n",
       "      <td>Overall, the risk minimisation measures includ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>119</th>\n",
       "      <td>120</td>\n",
       "      <td>Of particular interest this FDC comprises two ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>120</th>\n",
       "      <td>121</td>\n",
       "      <td>In the HCV GT1-infected population (the most w...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>121</th>\n",
       "      <td>122</td>\n",
       "      <td>As part of the response to CHMP questions thro...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>122</th>\n",
       "      <td>123</td>\n",
       "      <td>CHMP thus acknowledged that the applicant’s pr...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>123</th>\n",
       "      <td>124</td>\n",
       "      <td>Nevertheless, CHMP noted that since the clinic...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>124</th>\n",
       "      <td>125</td>\n",
       "      <td>The safety profile of Maviret (glecaprevir/pib...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>125</th>\n",
       "      <td>126</td>\n",
       "      <td>While the risk of ALT elevations seems lower a...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>126</th>\n",
       "      <td>127</td>\n",
       "      <td>This has been appropriately covered in the Mav...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>127</th>\n",
       "      <td>128</td>\n",
       "      <td>To support the application, the applicant has ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>128</th>\n",
       "      <td>129</td>\n",
       "      <td>It was a randomized, blind, 1-way parallel bio...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>129</th>\n",
       "      <td>130</td>\n",
       "      <td>The concerns raised during the procedure regar...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>130</th>\n",
       "      <td>131</td>\n",
       "      <td>No additional clinical studies were provided w...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>131</th>\n",
       "      <td>132</td>\n",
       "      <td>A clinical overview has been provided and was ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>132</th>\n",
       "      <td>133</td>\n",
       "      <td>The CHMP considered this application acceptabl...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>133</th>\n",
       "      <td>134</td>\n",
       "      <td>A summary of the literature with regard to cli...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>134</th>\n",
       "      <td>135</td>\n",
       "      <td>This is in accordance with the relevant guidel...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>135</th>\n",
       "      <td>136</td>\n",
       "      <td>A single dose bioequivalence study was conside...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>136</th>\n",
       "      <td>137</td>\n",
       "      <td>Biosimilarity of CT-P10 and MabThera is consid...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>137</th>\n",
       "      <td>138</td>\n",
       "      <td>In the pivotal RA trial, efficacy results in t...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>138</th>\n",
       "      <td>139</td>\n",
       "      <td>In addition, PK data discussed support the ext...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>139</th>\n",
       "      <td>140</td>\n",
       "      <td>The objectives of study CT-P10 3.3 were to dem...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>140</th>\n",
       "      <td>141</td>\n",
       "      <td>The overall safety profile of CT-P10 appeared ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>141</th>\n",
       "      <td>142</td>\n",
       "      <td>Therefore, the available safety data are consi...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>142</th>\n",
       "      <td>143</td>\n",
       "      <td>Most common reported events were infections, i...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>143</th>\n",
       "      <td>144</td>\n",
       "      <td>The frequencies and nature of the adverse even...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>144</th>\n",
       "      <td>145</td>\n",
       "      <td>Although dataset of AFL patients has been upda...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>145</th>\n",
       "      <td>146</td>\n",
       "      <td>Additional safety data from Maintenance Study ...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>146</th>\n",
       "      <td>147</td>\n",
       "      <td>The planned extension studies CT-P10 3.2 (RA) ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>147</th>\n",
       "      <td>148</td>\n",
       "      <td>Biosimilarity of CT-P10 and MabThera is consid...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>148</th>\n",
       "      <td>149</td>\n",
       "      <td>In the pivotal RA trial, efficacy results in t...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>149</th>\n",
       "      <td>150</td>\n",
       "      <td>In addition, PK data discussed support the ext...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>150</th>\n",
       "      <td>151</td>\n",
       "      <td>The objectives of study CT-P10 3.3 were to dem...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>151</th>\n",
       "      <td>152</td>\n",
       "      <td>The overall safety profile of CT-P10 appeared ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>152</th>\n",
       "      <td>153</td>\n",
       "      <td>Therefore, the available safety data are consi...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>153</th>\n",
       "      <td>154</td>\n",
       "      <td>Most common reported events were infections, i...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>154</th>\n",
       "      <td>155</td>\n",
       "      <td>The frequencies and nature of the adverse even...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>155</th>\n",
       "      <td>156</td>\n",
       "      <td>Although dataset of AFL patients has been upda...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>156</th>\n",
       "      <td>157</td>\n",
       "      <td>Additional safety data from Maintenance Study ...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>157</th>\n",
       "      <td>158</td>\n",
       "      <td>The planned extension studies CT-P10 3.2 (RA) ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>158</th>\n",
       "      <td>159</td>\n",
       "      <td>The results presented on efficacy support the ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>159</th>\n",
       "      <td>160</td>\n",
       "      <td>The number of subjects is sufficient for compa...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>160</th>\n",
       "      <td>161</td>\n",
       "      <td>Broadly, the number, severity and type of TEAE...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>161</th>\n",
       "      <td>162</td>\n",
       "      <td>The frequency of related AEs, severity of AEs ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>162</th>\n",
       "      <td>163</td>\n",
       "      <td>More detailed data on injection site reactions...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>163</th>\n",
       "      <td>164</td>\n",
       "      <td>The submitted additional analyses further supp...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>164</th>\n",
       "      <td>165</td>\n",
       "      <td>With regard to immunogenicity, the incidence a...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>165</th>\n",
       "      <td>166</td>\n",
       "      <td>No worsening of the immunogenicity profile was...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>166</th>\n",
       "      <td>167</td>\n",
       "      <td>Since Rolufta application is an informed conse...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>167</th>\n",
       "      <td>168</td>\n",
       "      <td>Overall, ABP 501 has in the RA study shown sim...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>168</th>\n",
       "      <td>169</td>\n",
       "      <td>The primary endpoint was met, and similarity a...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>169</th>\n",
       "      <td>170</td>\n",
       "      <td>Also mean change in DAS28-CRP showed high simi...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>170</th>\n",
       "      <td>171</td>\n",
       "      <td>ACR20 results per visit showed significant dif...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>171</th>\n",
       "      <td>172</td>\n",
       "      <td>However, these results are not seen for DAS28 ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>172</th>\n",
       "      <td>173</td>\n",
       "      <td>Also the psoriasis study met the primary endpo...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>173</th>\n",
       "      <td>174</td>\n",
       "      <td>The secondary endpoints PASI 75 and sPGA showe...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>174</th>\n",
       "      <td>175</td>\n",
       "      <td>Overall, clinical similarity between ABP 501 a...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>175</th>\n",
       "      <td>176</td>\n",
       "      <td>The safety profile of ABP 501 and Humira is co...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>176</th>\n",
       "      <td>177</td>\n",
       "      <td>The majority of treated infants with infantile...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>177</th>\n",
       "      <td>178</td>\n",
       "      <td>Data from treated pre-symptomatic infants with...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>178</th>\n",
       "      <td>179</td>\n",
       "      <td>Subjects with later-onset SMA who received nus...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>179</th>\n",
       "      <td>180</td>\n",
       "      <td>The difference in magnitude across endpoints i...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>180</th>\n",
       "      <td>181</td>\n",
       "      <td>Data from the ongoing studies in infantile-ons...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>181</th>\n",
       "      <td>182</td>\n",
       "      <td>They also support the need for early treatment...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>182</th>\n",
       "      <td>183</td>\n",
       "      <td>Taken together, these data demonstrate consist...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>183</th>\n",
       "      <td>184</td>\n",
       "      <td>The consistency among the various key clinical...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>184</th>\n",
       "      <td>185</td>\n",
       "      <td>The current studies do not provide evidence th...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>185</th>\n",
       "      <td>186</td>\n",
       "      <td>The CHMP considers the following measures as k...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>186</th>\n",
       "      <td>187</td>\n",
       "      <td>PAES: In order to evaluate the long term effic...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>187</th>\n",
       "      <td>188</td>\n",
       "      <td>the MAH should conduct and submit the results ...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>188</th>\n",
       "      <td>189</td>\n",
       "      <td>• PAES: In order to evaluate the long term eff...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>189</th>\n",
       "      <td>190</td>\n",
       "      <td>Along with the needed data on efficacy and saf...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>190</th>\n",
       "      <td>191</td>\n",
       "      <td>These are being used to collect the required P...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>191</th>\n",
       "      <td>192</td>\n",
       "      <td>CSF data are being collected from both these s...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>192</th>\n",
       "      <td>193</td>\n",
       "      <td>Additionally, the following measures will cont...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>193</th>\n",
       "      <td>194</td>\n",
       "      <td>• EMBRACE (SM202) - Phase 2, randomized, doubl...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>194</th>\n",
       "      <td>195</td>\n",
       "      <td>• Registries initiative - Collaborations with ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>195</th>\n",
       "      <td>196</td>\n",
       "      <td>• Exploring higher doses - The company is requ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>196</th>\n",
       "      <td>197</td>\n",
       "      <td>The safety profile of nusinersen was character...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>197</th>\n",
       "      <td>198</td>\n",
       "      <td>Review of the available data demonstrated no s...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>198</th>\n",
       "      <td>199</td>\n",
       "      <td>The majority of AEs and SAEs reported in subje...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>199</th>\n",
       "      <td>200</td>\n",
       "      <td>Pre-symptomatic infants treated with nusinerse...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>200</th>\n",
       "      <td>201</td>\n",
       "      <td>In addition, the fatality rate in nusinersen-t...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>201</th>\n",
       "      <td>202</td>\n",
       "      <td>nusinersen has demonstrated a favourable safet...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>202</th>\n",
       "      <td>203</td>\n",
       "      <td>This was supported by favourable safety and ef...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>203</th>\n",
       "      <td>204</td>\n",
       "      <td>Based on the totality of the data, it can be a...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>204</th>\n",
       "      <td>205</td>\n",
       "      <td>Long-term safety data will be obtained from th...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>205</th>\n",
       "      <td>206</td>\n",
       "      <td>The FRC has been investigated in a clinical pr...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>206</th>\n",
       "      <td>207</td>\n",
       "      <td>The FRC is provided in two different pens with...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>207</th>\n",
       "      <td>208</td>\n",
       "      <td>Study EFC12404 provides relevant information o...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>208</th>\n",
       "      <td>209</td>\n",
       "      <td>Insulin glargine primarily reduces HbA1c by de...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>209</th>\n",
       "      <td>210</td>\n",
       "      <td>The major contribution in HbA1c is due to insu...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>210</th>\n",
       "      <td>211</td>\n",
       "      <td>With the FRC, the decrease in HbA1c was achiev...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>211</th>\n",
       "      <td>212</td>\n",
       "      <td>There was no difference in insulin dose with t...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>212</th>\n",
       "      <td>213</td>\n",
       "      <td>The effect was consistent across studies and a...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>213</th>\n",
       "      <td>214</td>\n",
       "      <td>In the studies, the FRC was always to be taken...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>214</th>\n",
       "      <td>215</td>\n",
       "      <td>It is acknowledged that both insulin glargine ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>215</th>\n",
       "      <td>216</td>\n",
       "      <td>The recommendation has been further supported ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>216</th>\n",
       "      <td>217</td>\n",
       "      <td>There is a lack of long-term data beyond 30 we...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>217</th>\n",
       "      <td>218</td>\n",
       "      <td>However, further analyses have shown that only...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>218</th>\n",
       "      <td>219</td>\n",
       "      <td>In addition, data from the lixisenatide file h...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>219</th>\n",
       "      <td>220</td>\n",
       "      <td>Thus it appears plausible that the effect can ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>220</th>\n",
       "      <td>221</td>\n",
       "      <td>No new or unexpected adverse reactions were no...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>221</th>\n",
       "      <td>222</td>\n",
       "      <td>The adverse reaction patterns differed however...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>222</th>\n",
       "      <td>223</td>\n",
       "      <td>The incidences of documented hypoglycaemic epi...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>223</th>\n",
       "      <td>224</td>\n",
       "      <td>However, it should be noted that concomitant u...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>224</th>\n",
       "      <td>225</td>\n",
       "      <td>Immunological reactions such as allergic react...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>225</th>\n",
       "      <td>226</td>\n",
       "      <td>A lower frequency of patients developed lixise...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>226</th>\n",
       "      <td>227</td>\n",
       "      <td>The RMP adequately reflects the safety concern...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>227</th>\n",
       "      <td>228</td>\n",
       "      <td>Overall, the fixed combination of lixisenatide...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>228</th>\n",
       "      <td>229</td>\n",
       "      <td>There are no major objections based on the eff...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>229</th>\n",
       "      <td>230</td>\n",
       "      <td>The separate components of the D/C/F/TAF fixed...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>230</th>\n",
       "      <td>231</td>\n",
       "      <td>Bioequivalence of the FDC to the separate comp...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>231</th>\n",
       "      <td>232</td>\n",
       "      <td>A non-inferior efficacy of D/C/F/TAF vs DRV+CO...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>232</th>\n",
       "      <td>233</td>\n",
       "      <td>Preliminary results from the ongoing phase 3 s...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>233</th>\n",
       "      <td>234</td>\n",
       "      <td>The safety profile of the D/C/F/TAF FDC is lar...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>234</th>\n",
       "      <td>235</td>\n",
       "      <td>The safety profile of D/C/F/TAF FDC is support...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>235</th>\n",
       "      <td>236</td>\n",
       "      <td>The observed safety profile is in line with ex...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>236</th>\n",
       "      <td>237</td>\n",
       "      <td>Since Tadalafil Lilly application is an inform...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>237</th>\n",
       "      <td>238</td>\n",
       "      <td>A summary of the literature with regard to cli...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>238</th>\n",
       "      <td>239</td>\n",
       "      <td>Study TRIPLE 5, triple therapy with BDP/FF/GB ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>239</th>\n",
       "      <td>240</td>\n",
       "      <td>TDI focal score, the third co-primary endpoint...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>240</th>\n",
       "      <td>241</td>\n",
       "      <td>Nevertheless, the responder analysis indicates...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>241</th>\n",
       "      <td>242</td>\n",
       "      <td>Also, the observed 23% reduction in the exacer...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>242</th>\n",
       "      <td>243</td>\n",
       "      <td>Study TRIPLE 6, CHF 5993 had a statistically s...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>243</th>\n",
       "      <td>244</td>\n",
       "      <td>The observed 20% reduction in the exacerbation...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>244</th>\n",
       "      <td>245</td>\n",
       "      <td>Superiority of CHF 5993 pMDI over Tiotropium a...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>245</th>\n",
       "      <td>246</td>\n",
       "      <td>The superior clinical efficacy of CHF 5993 pMD...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>246</th>\n",
       "      <td>247</td>\n",
       "      <td>For these parameters, CHF 5993 pMDI and Foster...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>247</th>\n",
       "      <td>248</td>\n",
       "      <td>Overall, CHF 5993 pMDI has shown benefits in r...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>248</th>\n",
       "      <td>249</td>\n",
       "      <td>From the safety data presented there are no pa...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>249</th>\n",
       "      <td>250</td>\n",
       "      <td>The main side effects that have been observed ...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>250</th>\n",
       "      <td>251</td>\n",
       "      <td>The clinical database is acceptable and consid...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>251</th>\n",
       "      <td>252</td>\n",
       "      <td>The clinical safety sections of the SmPC conta...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>252</th>\n",
       "      <td>253</td>\n",
       "      <td>In this informed consent application, there ar...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>253</th>\n",
       "      <td>254</td>\n",
       "      <td>All the clinical data have been assessed for N...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>254</th>\n",
       "      <td>255</td>\n",
       "      <td>SOF/VEL/VOX for 12 weeks has shown excellent e...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>255</th>\n",
       "      <td>256</td>\n",
       "      <td>A similar 12 week course appears somewhat bett...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>256</th>\n",
       "      <td>257</td>\n",
       "      <td>An 8 week course of SOF/VEL/VOX was similarly ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>257</th>\n",
       "      <td>258</td>\n",
       "      <td>Further, an 8 week course of SOF/VEL/VOX showe...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>258</th>\n",
       "      <td>259</td>\n",
       "      <td>The addition of VOX appears to increase the ba...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>259</th>\n",
       "      <td>260</td>\n",
       "      <td>Conclusions concerning recommended use are dis...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>260</th>\n",
       "      <td>261</td>\n",
       "      <td>SOF/VEL/VOX has been studied in a sufficient n...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>261</th>\n",
       "      <td>262</td>\n",
       "      <td>Compared to SOF/VEL and placebo, there were si...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>262</th>\n",
       "      <td>263</td>\n",
       "      <td>Other potentially related AE’s including decre...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>263</th>\n",
       "      <td>264</td>\n",
       "      <td>No treatment-related SAE was reported and only...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>264</th>\n",
       "      <td>265</td>\n",
       "      <td>There was no general indication of VOX-associa...</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>265</th>\n",
       "      <td>266</td>\n",
       "      <td>The safety profile of SOF/VEL/VOX for 8 or 12 ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "      ID                                           Sentence  Positive  \\\n",
       "0      1  The results in 2nd line treatment show an ORR ...         1   \n",
       "1      2  The long duration of response and high durable...         1   \n",
       "2      3  The median OS time in the updated results exce...         0   \n",
       "3      4  Therefore, the clinical benefit in 2nd line tr...         1   \n",
       "4      5  The data provided in 1st line, although prelim...         1   \n",
       "5      6  Taking into account the intrinsic limitation o...         1   \n",
       "6      7  This medicinal product has been authorised und...         0   \n",
       "7      8  This means that further evidence on this medic...         0   \n",
       "8      9  The European Medicines Agency will review new ...         0   \n",
       "9     10  The CHMP considers the following measures nece...         0   \n",
       "10    11  In order to confirm the efficacy for chemother...         0   \n",
       "11    12  The final results of the study should be submi...         0   \n",
       "12    13  The CHMP considers that additional supportive ...         0   \n",
       "13    14  • PASS: German real-world cohort study should ...         0   \n",
       "14    15  The safety data collected at an earlier data c...         1   \n",
       "15    16  No major concerns have been identified in the ...         1   \n",
       "16    17  The safety of avelumab in the proposed indicat...         1   \n",
       "17    18  The safety risks associated with immune relate...         0   \n",
       "18    19  The CHMP considers the following measures nece...         0   \n",
       "19    20  • PASS: German real-world cohort study should ...         0   \n",
       "20    21  Biosimilarity of CT-P10 and MabThera is consid...         1   \n",
       "21    22  In the pivotal RA trial, efficacy results in t...         1   \n",
       "22    23  In addition, PK data discussed support the ext...         1   \n",
       "23    24  The objectives of study CT-P10 3.3 were to dem...         1   \n",
       "24    25  The overall safety profile of CT-P10 appeared ...         0   \n",
       "25    26  Therefore, the available safety data are consi...         1   \n",
       "26    27  Most common reported events were infections, i...         0   \n",
       "27    28  The frequencies and nature of the adverse even...         1   \n",
       "28    29  Although dataset of AFL patients has been upda...         0   \n",
       "29    30  Additional safety data from maintenance study ...         0   \n",
       "30    31  The planned extension studies CT-P10 3.2 (RA) ...         0   \n",
       "31    32  A summary of the literature with regard to cli...         1   \n",
       "32    33  This is in accordance with the relevant guidel...         1   \n",
       "33    34  The superiority to placebo was demonstrated fo...         1   \n",
       "34    35  No significant additional benefit was observed...         0   \n",
       "35    36  Therefore, the CHMP endorsed the proposed dose...         0   \n",
       "36    37  Based on the presented and available data, dup...         1   \n",
       "37    38  With regard to TEAE profile, no meaningful qua...         0   \n",
       "38    39  As questions still remain on the long term saf...         0   \n",
       "39    40  The applicant provided six pivotal studies to ...         0   \n",
       "40    41  Only 3 pivotal randomized double-blind multice...         0   \n",
       "41    42  Based on the primary meta-analysis conducted b...         0   \n",
       "42    43  This benefit difference (PPS versus placebo) r...         0   \n",
       "43    44  Indeed, this benefit difference was mainly dri...         0   \n",
       "44    45  Furthermore according to the meta-analysis of ...         1   \n",
       "45    46  Overall, the safety profile of PPS is not cons...         1   \n",
       "46    47  Due to the heparin-like structure of PPS, a we...         0   \n",
       "47    48  This risk is adequately addressed in various s...         1   \n",
       "48    49  Based on the presented bioequivalence study th...         1   \n",
       "49    50  The application contains an adequate review of...         1   \n",
       "50    51  A biowaiver for the 20 mg strength is consider...         1   \n",
       "51    52  Based on the presented bioequivalence study Gr...         1   \n",
       "52    53  The results of study 084-09 with 100mg formula...         1   \n",
       "53    54  The results presented on efficacy support the ...         1   \n",
       "54    55  The number of subjects is sufficient for compa...         1   \n",
       "55    56  Broadly, the number, severity and type of TEAE...         1   \n",
       "56    57  The frequency of related AEs, severity of AEs ...         1   \n",
       "57    58  More detailed data on injection site reactions...         0   \n",
       "58    59  The submitted additional analyses further supp...         1   \n",
       "59    60  With regard to immunogenicity, the incidence a...         1   \n",
       "60    61  No worsening of the immunogenicity profile was...         1   \n",
       "61    62  There was no clinical efficacy study performed...         0   \n",
       "62    63  In light of established biosimilarity on quali...         1   \n",
       "63    64  For the purpose of the clinical biosimilarity ...         0   \n",
       "64    65  1).Nevertheless, the applicant has conducted t...         0   \n",
       "65    66  This data is considered supportive in establis...         1   \n",
       "66    67  Both studies, demonstrated that SAR342434 is n...         1   \n",
       "67    68  The 12-month results of study EFC12619 further...         1   \n",
       "68    69  The size of the safety database and duration o...         1   \n",
       "69    70  Safety and tolerability of Insulin lispro Sano...         1   \n",
       "70    71  With regard to immunogenicity, the differences...         0   \n",
       "71    72  Treatment-emergent AIA did not affect efficacy...         1   \n",
       "72    73  In conclusion, the safety profile of Insulin l...         1   \n",
       "73    74  The bioequivalence of the applied product Ivab...         1   \n",
       "74    75  The study has been performed under fed conditi...         1   \n",
       "75    76  The sample size was calculated to provide adeq...         1   \n",
       "76    77  The statistical methodology used in the studie...         1   \n",
       "77    78  In accordance with the study protocol the stud...         1   \n",
       "78    79  The bioequivalence study appears to have been ...         1   \n",
       "79    80  An acceptable justification for a biowaiver of...         1   \n",
       "80    81  to the EMA Guideline on the Investigation of B...         1   \n",
       "81    82  The efficacy data of the two phase 3 placebo-c...         1   \n",
       "82    83  The active-comparator study demonstrated the e...         1   \n",
       "83    84  Overall, data of the submitted studies are con...         1   \n",
       "84    85  The safety observation is based on a total of ...         0   \n",
       "85    86  Sarilumab is associated with infections (inclu...         0   \n",
       "86    87  No new safety concerns were identified during ...         1   \n",
       "87    88  The efficacy of the combination of lenvatinib ...         1   \n",
       "88    89  Lenvatinib/everolimus combination therapy demo...         1   \n",
       "89    90  Additional sensitivity analyses performed conf...         1   \n",
       "90    91  Furthermore, encouraging signs of a prolonged ...         1   \n",
       "91    92  A similar trend towards prolonged OS was also ...         1   \n",
       "92    93  The overall safety profile of lenvatinib-evero...         1   \n",
       "93    94  The reported toxicity was in general predictab...         1   \n",
       "94    95            No new safety signal has been reported.         1   \n",
       "95    96  However, most of these adverse events were wel...         1   \n",
       "96    97  However, precaution is warranted given a small...         0   \n",
       "97    98  Although toxicity appears to be manageable wit...         0   \n",
       "98    99  Poor tolerability of the combination is manife...         0   \n",
       "99   100  Therefore, further studies need to be conducte...         0   \n",
       "100  101  The CHMP considers the following measures nece...         0   \n",
       "101  102  Study 307 is requested to further characterise...         0   \n",
       "102  103  Study 221 will continue to characterize safety...         0   \n",
       "103  104  Study 010 will assess in vitro lenvatinib prot...         0   \n",
       "104  105  Studies requested for Lenvima will also provid...         0   \n",
       "105  106  Based on the available data, the CHMP consider...         1   \n",
       "106  107  Therefore the absence of a bioequivalence stud...         1   \n",
       "107  108  Overall, the available clinical efficacy data ...         1   \n",
       "108  109  Results from the pivotal study CLARITY showed ...         1   \n",
       "109  110  Subgroup analyses suggested a larger effect si...         0   \n",
       "110  111  Furthermore, data in SPMS patients with superi...         1   \n",
       "111  112  Based on these data and since relapses in both...         0   \n",
       "112  113  The data furthermore support the use of a cumu...         1   \n",
       "113  114  Maintenance of the treatment effect in year 3 ...         1   \n",
       "114  115  No clinically relevant added benefit of additi...         0   \n",
       "115  116  Overall, the CHMP was of the view that the ava...         1   \n",
       "116  117  The main safety issues were related to the ris...         0   \n",
       "117  118  For the latter, uncertainties due to the obser...         0   \n",
       "118  119  Overall, the risk minimisation measures includ...         1   \n",
       "119  120  Of particular interest this FDC comprises two ...         0   \n",
       "120  121  In the HCV GT1-infected population (the most w...         1   \n",
       "121  122  As part of the response to CHMP questions thro...         0   \n",
       "122  123  CHMP thus acknowledged that the applicant’s pr...         1   \n",
       "123  124  Nevertheless, CHMP noted that since the clinic...         0   \n",
       "124  125  The safety profile of Maviret (glecaprevir/pib...         1   \n",
       "125  126  While the risk of ALT elevations seems lower a...         0   \n",
       "126  127  This has been appropriately covered in the Mav...         1   \n",
       "127  128  To support the application, the applicant has ...         0   \n",
       "128  129  It was a randomized, blind, 1-way parallel bio...         0   \n",
       "129  130  The concerns raised during the procedure regar...         1   \n",
       "130  131  No additional clinical studies were provided w...         0   \n",
       "131  132  A clinical overview has been provided and was ...         0   \n",
       "132  133  The CHMP considered this application acceptabl...         1   \n",
       "133  134  A summary of the literature with regard to cli...         1   \n",
       "134  135  This is in accordance with the relevant guidel...         1   \n",
       "135  136  A single dose bioequivalence study was conside...         1   \n",
       "136  137  Biosimilarity of CT-P10 and MabThera is consid...         1   \n",
       "137  138  In the pivotal RA trial, efficacy results in t...         1   \n",
       "138  139  In addition, PK data discussed support the ext...         1   \n",
       "139  140  The objectives of study CT-P10 3.3 were to dem...         1   \n",
       "140  141  The overall safety profile of CT-P10 appeared ...         0   \n",
       "141  142  Therefore, the available safety data are consi...         1   \n",
       "142  143  Most common reported events were infections, i...         0   \n",
       "143  144  The frequencies and nature of the adverse even...         1   \n",
       "144  145  Although dataset of AFL patients has been upda...         0   \n",
       "145  146  Additional safety data from Maintenance Study ...         0   \n",
       "146  147  The planned extension studies CT-P10 3.2 (RA) ...         0   \n",
       "147  148  Biosimilarity of CT-P10 and MabThera is consid...         1   \n",
       "148  149  In the pivotal RA trial, efficacy results in t...         1   \n",
       "149  150  In addition, PK data discussed support the ext...         1   \n",
       "150  151  The objectives of study CT-P10 3.3 were to dem...         1   \n",
       "151  152  The overall safety profile of CT-P10 appeared ...         0   \n",
       "152  153  Therefore, the available safety data are consi...         1   \n",
       "153  154  Most common reported events were infections, i...         0   \n",
       "154  155  The frequencies and nature of the adverse even...         1   \n",
       "155  156  Although dataset of AFL patients has been upda...         0   \n",
       "156  157  Additional safety data from Maintenance Study ...         0   \n",
       "157  158  The planned extension studies CT-P10 3.2 (RA) ...         0   \n",
       "158  159  The results presented on efficacy support the ...         1   \n",
       "159  160  The number of subjects is sufficient for compa...         1   \n",
       "160  161  Broadly, the number, severity and type of TEAE...         1   \n",
       "161  162  The frequency of related AEs, severity of AEs ...         1   \n",
       "162  163  More detailed data on injection site reactions...         0   \n",
       "163  164  The submitted additional analyses further supp...         1   \n",
       "164  165  With regard to immunogenicity, the incidence a...         1   \n",
       "165  166  No worsening of the immunogenicity profile was...         1   \n",
       "166  167  Since Rolufta application is an informed conse...         1   \n",
       "167  168  Overall, ABP 501 has in the RA study shown sim...         1   \n",
       "168  169  The primary endpoint was met, and similarity a...         1   \n",
       "169  170  Also mean change in DAS28-CRP showed high simi...         1   \n",
       "170  171  ACR20 results per visit showed significant dif...         0   \n",
       "171  172  However, these results are not seen for DAS28 ...         1   \n",
       "172  173  Also the psoriasis study met the primary endpo...         1   \n",
       "173  174  The secondary endpoints PASI 75 and sPGA showe...         0   \n",
       "174  175  Overall, clinical similarity between ABP 501 a...         1   \n",
       "175  176  The safety profile of ABP 501 and Humira is co...         1   \n",
       "176  177  The majority of treated infants with infantile...         1   \n",
       "177  178  Data from treated pre-symptomatic infants with...         1   \n",
       "178  179  Subjects with later-onset SMA who received nus...         1   \n",
       "179  180  The difference in magnitude across endpoints i...         0   \n",
       "180  181  Data from the ongoing studies in infantile-ons...         1   \n",
       "181  182  They also support the need for early treatment...         1   \n",
       "182  183  Taken together, these data demonstrate consist...         1   \n",
       "183  184  The consistency among the various key clinical...         1   \n",
       "184  185  The current studies do not provide evidence th...         0   \n",
       "185  186  The CHMP considers the following measures as k...         0   \n",
       "186  187  PAES: In order to evaluate the long term effic...         0   \n",
       "187  188  the MAH should conduct and submit the results ...         0   \n",
       "188  189  • PAES: In order to evaluate the long term eff...         0   \n",
       "189  190  Along with the needed data on efficacy and saf...         0   \n",
       "190  191  These are being used to collect the required P...         0   \n",
       "191  192  CSF data are being collected from both these s...         0   \n",
       "192  193  Additionally, the following measures will cont...         0   \n",
       "193  194  • EMBRACE (SM202) - Phase 2, randomized, doubl...         0   \n",
       "194  195  • Registries initiative - Collaborations with ...         0   \n",
       "195  196  • Exploring higher doses - The company is requ...         0   \n",
       "196  197  The safety profile of nusinersen was character...         0   \n",
       "197  198  Review of the available data demonstrated no s...         1   \n",
       "198  199  The majority of AEs and SAEs reported in subje...         1   \n",
       "199  200  Pre-symptomatic infants treated with nusinerse...         0   \n",
       "200  201  In addition, the fatality rate in nusinersen-t...         1   \n",
       "201  202  nusinersen has demonstrated a favourable safet...         1   \n",
       "202  203  This was supported by favourable safety and ef...         1   \n",
       "203  204  Based on the totality of the data, it can be a...         1   \n",
       "204  205  Long-term safety data will be obtained from th...         0   \n",
       "205  206  The FRC has been investigated in a clinical pr...         1   \n",
       "206  207  The FRC is provided in two different pens with...         0   \n",
       "207  208  Study EFC12404 provides relevant information o...         1   \n",
       "208  209  Insulin glargine primarily reduces HbA1c by de...         0   \n",
       "209  210  The major contribution in HbA1c is due to insu...         0   \n",
       "210  211  With the FRC, the decrease in HbA1c was achiev...         1   \n",
       "211  212  There was no difference in insulin dose with t...         0   \n",
       "212  213  The effect was consistent across studies and a...         0   \n",
       "213  214  In the studies, the FRC was always to be taken...         0   \n",
       "214  215  It is acknowledged that both insulin glargine ...         0   \n",
       "215  216  The recommendation has been further supported ...         0   \n",
       "216  217  There is a lack of long-term data beyond 30 we...         0   \n",
       "217  218  However, further analyses have shown that only...         1   \n",
       "218  219  In addition, data from the lixisenatide file h...         1   \n",
       "219  220  Thus it appears plausible that the effect can ...         1   \n",
       "220  221  No new or unexpected adverse reactions were no...         1   \n",
       "221  222  The adverse reaction patterns differed however...         0   \n",
       "222  223  The incidences of documented hypoglycaemic epi...         1   \n",
       "223  224  However, it should be noted that concomitant u...         0   \n",
       "224  225  Immunological reactions such as allergic react...         1   \n",
       "225  226  A lower frequency of patients developed lixise...         1   \n",
       "226  227  The RMP adequately reflects the safety concern...         1   \n",
       "227  228  Overall, the fixed combination of lixisenatide...         1   \n",
       "228  229  There are no major objections based on the eff...         1   \n",
       "229  230  The separate components of the D/C/F/TAF fixed...         0   \n",
       "230  231  Bioequivalence of the FDC to the separate comp...         1   \n",
       "231  232  A non-inferior efficacy of D/C/F/TAF vs DRV+CO...         0   \n",
       "232  233  Preliminary results from the ongoing phase 3 s...         1   \n",
       "233  234  The safety profile of the D/C/F/TAF FDC is lar...         1   \n",
       "234  235  The safety profile of D/C/F/TAF FDC is support...         1   \n",
       "235  236  The observed safety profile is in line with ex...         1   \n",
       "236  237  Since Tadalafil Lilly application is an inform...         1   \n",
       "237  238  A summary of the literature with regard to cli...         1   \n",
       "238  239  Study TRIPLE 5, triple therapy with BDP/FF/GB ...         1   \n",
       "239  240  TDI focal score, the third co-primary endpoint...         0   \n",
       "240  241  Nevertheless, the responder analysis indicates...         1   \n",
       "241  242  Also, the observed 23% reduction in the exacer...         1   \n",
       "242  243  Study TRIPLE 6, CHF 5993 had a statistically s...         1   \n",
       "243  244  The observed 20% reduction in the exacerbation...         1   \n",
       "244  245  Superiority of CHF 5993 pMDI over Tiotropium a...         1   \n",
       "245  246  The superior clinical efficacy of CHF 5993 pMD...         1   \n",
       "246  247  For these parameters, CHF 5993 pMDI and Foster...         0   \n",
       "247  248  Overall, CHF 5993 pMDI has shown benefits in r...         1   \n",
       "248  249  From the safety data presented there are no pa...         1   \n",
       "249  250  The main side effects that have been observed ...         0   \n",
       "250  251  The clinical database is acceptable and consid...         1   \n",
       "251  252  The clinical safety sections of the SmPC conta...         1   \n",
       "252  253  In this informed consent application, there ar...         1   \n",
       "253  254  All the clinical data have been assessed for N...         1   \n",
       "254  255  SOF/VEL/VOX for 12 weeks has shown excellent e...         1   \n",
       "255  256  A similar 12 week course appears somewhat bett...         1   \n",
       "256  257  An 8 week course of SOF/VEL/VOX was similarly ...         1   \n",
       "257  258  Further, an 8 week course of SOF/VEL/VOX showe...         0   \n",
       "258  259  The addition of VOX appears to increase the ba...         0   \n",
       "259  260  Conclusions concerning recommended use are dis...         0   \n",
       "260  261  SOF/VEL/VOX has been studied in a sufficient n...         1   \n",
       "261  262  Compared to SOF/VEL and placebo, there were si...         1   \n",
       "262  263  Other potentially related AE’s including decre...         0   \n",
       "263  264  No treatment-related SAE was reported and only...         1   \n",
       "264  265  There was no general indication of VOX-associa...         0   \n",
       "265  266  The safety profile of SOF/VEL/VOX for 8 or 12 ...         1   \n",
       "\n",
       "     Negative  Neutral  \n",
       "0           0        0  \n",
       "1           0        0  \n",
       "2           0        1  \n",
       "3           0        0  \n",
       "4           0        0  \n",
       "5           0        0  \n",
       "6           0        1  \n",
       "7           1        0  \n",
       "8           0        1  \n",
       "9           1        0  \n",
       "10          0        1  \n",
       "11          0        1  \n",
       "12          0        1  \n",
       "13          1        0  \n",
       "14          0        0  \n",
       "15          0        0  \n",
       "16          0        0  \n",
       "17          0        1  \n",
       "18          1        0  \n",
       "19          1        0  \n",
       "20          0        0  \n",
       "21          0        0  \n",
       "22          0        0  \n",
       "23          0        0  \n",
       "24          0        1  \n",
       "25          0        0  \n",
       "26          0        1  \n",
       "27          0        0  \n",
       "28          1        0  \n",
       "29          1        0  \n",
       "30          0        1  \n",
       "31          0        0  \n",
       "32          0        0  \n",
       "33          0        0  \n",
       "34          0        1  \n",
       "35          0        1  \n",
       "36          0        0  \n",
       "37          0        1  \n",
       "38          1        0  \n",
       "39          0        1  \n",
       "40          1        0  \n",
       "41          0        1  \n",
       "42          0        1  \n",
       "43          0        1  \n",
       "44          0        0  \n",
       "45          0        0  \n",
       "46          1        0  \n",
       "47          0        0  \n",
       "48          0        0  \n",
       "49          0        0  \n",
       "50          0        0  \n",
       "51          0        0  \n",
       "52          0        0  \n",
       "53          0        0  \n",
       "54          0        0  \n",
       "55          0        0  \n",
       "56          0        0  \n",
       "57          1        0  \n",
       "58          0        0  \n",
       "59          0        0  \n",
       "60          0        0  \n",
       "61          0        1  \n",
       "62          0        0  \n",
       "63          0        1  \n",
       "64          0        1  \n",
       "65          0        0  \n",
       "66          0        0  \n",
       "67          0        0  \n",
       "68          0        0  \n",
       "69          0        0  \n",
       "70          1        0  \n",
       "71          0        0  \n",
       "72          0        0  \n",
       "73          0        0  \n",
       "74          0        0  \n",
       "75          0        0  \n",
       "76          0        0  \n",
       "77          0        0  \n",
       "78          0        0  \n",
       "79          0        0  \n",
       "80          0        0  \n",
       "81          0        0  \n",
       "82          0        0  \n",
       "83          0        0  \n",
       "84          0        1  \n",
       "85          0        1  \n",
       "86          0        0  \n",
       "87          0        0  \n",
       "88          0        0  \n",
       "89          0        0  \n",
       "90          0        0  \n",
       "91          0        0  \n",
       "92          0        0  \n",
       "93          0        0  \n",
       "94          0        0  \n",
       "95          0        0  \n",
       "96          1        0  \n",
       "97          1        0  \n",
       "98          1        0  \n",
       "99          1        0  \n",
       "100         1        0  \n",
       "101         1        0  \n",
       "102         0        1  \n",
       "103         0        1  \n",
       "104         1        0  \n",
       "105         0        0  \n",
       "106         0        0  \n",
       "107         0        0  \n",
       "108         0        0  \n",
       "109         0        1  \n",
       "110         0        0  \n",
       "111         1        0  \n",
       "112         0        0  \n",
       "113         0        0  \n",
       "114         0        1  \n",
       "115         0        0  \n",
       "116         0        1  \n",
       "117         0        1  \n",
       "118         0        0  \n",
       "119         0        1  \n",
       "120         0        0  \n",
       "121         0        1  \n",
       "122         0        0  \n",
       "123         1        0  \n",
       "124         0        0  \n",
       "125         0        1  \n",
       "126         0        0  \n",
       "127         0        1  \n",
       "128         0        1  \n",
       "129         0        0  \n",
       "130         0        1  \n",
       "131         0        1  \n",
       "132         0        0  \n",
       "133         0        0  \n",
       "134         0        0  \n",
       "135         0        0  \n",
       "136         0        0  \n",
       "137         0        0  \n",
       "138         0        0  \n",
       "139         0        0  \n",
       "140         0        1  \n",
       "141         0        0  \n",
       "142         0        1  \n",
       "143         0        0  \n",
       "144         1        0  \n",
       "145         1        0  \n",
       "146         0        1  \n",
       "147         0        0  \n",
       "148         0        0  \n",
       "149         0        0  \n",
       "150         0        0  \n",
       "151         0        1  \n",
       "152         0        0  \n",
       "153         0        1  \n",
       "154         0        0  \n",
       "155         1        0  \n",
       "156         1        0  \n",
       "157         0        1  \n",
       "158         0        0  \n",
       "159         0        0  \n",
       "160         0        0  \n",
       "161         0        0  \n",
       "162         1        0  \n",
       "163         0        0  \n",
       "164         0        0  \n",
       "165         0        0  \n",
       "166         0        0  \n",
       "167         0        0  \n",
       "168         0        0  \n",
       "169         0        0  \n",
       "170         1        0  \n",
       "171         0        0  \n",
       "172         0        0  \n",
       "173         0        1  \n",
       "174         0        0  \n",
       "175         0        0  \n",
       "176         0        0  \n",
       "177         0        0  \n",
       "178         0        0  \n",
       "179         0        1  \n",
       "180         0        0  \n",
       "181         0        0  \n",
       "182         0        0  \n",
       "183         0        0  \n",
       "184         1        0  \n",
       "185         1        0  \n",
       "186         1        0  \n",
       "187         1        0  \n",
       "188         1        0  \n",
       "189         0        1  \n",
       "190         0        1  \n",
       "191         0        1  \n",
       "192         0        1  \n",
       "193         0        1  \n",
       "194         0        1  \n",
       "195         0        1  \n",
       "196         0        1  \n",
       "197         0        0  \n",
       "198         0        0  \n",
       "199         0        1  \n",
       "200         0        0  \n",
       "201         0        0  \n",
       "202         0        0  \n",
       "203         0        0  \n",
       "204         0        1  \n",
       "205         0        0  \n",
       "206         1        0  \n",
       "207         0        0  \n",
       "208         0        1  \n",
       "209         0        1  \n",
       "210         0        0  \n",
       "211         0        1  \n",
       "212         0        1  \n",
       "213         0        1  \n",
       "214         0        1  \n",
       "215         0        1  \n",
       "216         1        0  \n",
       "217         0        0  \n",
       "218         0        0  \n",
       "219         0        0  \n",
       "220         0        0  \n",
       "221         0        1  \n",
       "222         0        0  \n",
       "223         0        1  \n",
       "224         0        0  \n",
       "225         0        0  \n",
       "226         0        0  \n",
       "227         0        0  \n",
       "228         0        0  \n",
       "229         0        1  \n",
       "230         0        0  \n",
       "231         0        1  \n",
       "232         0        0  \n",
       "233         0        0  \n",
       "234         0        0  \n",
       "235         0        0  \n",
       "236         0        0  \n",
       "237         0        0  \n",
       "238         0        0  \n",
       "239         0        1  \n",
       "240         0        0  \n",
       "241         0        0  \n",
       "242         0        0  \n",
       "243         0        0  \n",
       "244         0        0  \n",
       "245         0        0  \n",
       "246         0        1  \n",
       "247         0        0  \n",
       "248         0        0  \n",
       "249         0        1  \n",
       "250         0        0  \n",
       "251         0        0  \n",
       "252         0        0  \n",
       "253         0        0  \n",
       "254         0        0  \n",
       "255         0        0  \n",
       "256         0        0  \n",
       "257         1        0  \n",
       "258         0        1  \n",
       "259         0        1  \n",
       "260         0        0  \n",
       "261         0        0  \n",
       "262         0        1  \n",
       "263         0        0  \n",
       "264         1        0  \n",
       "265         0        0  "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "coH-eOfaSRGi"
   },
   "source": [
    "# Data Inspection and Analysis\n",
    "Research Questions\n",
    "\n",
    "• Is the dataset balanced?\n",
    "\n",
    "• Is the amount of data sufficient for allowing a hold-out dataset?\n",
    "\n",
    "• Do you have enough data to consider deep neural architectures or\n",
    "might good feature engineering with more shallow models suffice?\n",
    "\n",
    "• During the data collection process, for some sentences multiple experts\n",
    "disagreed on the sentiment of a given sentence, how could you capture\n",
    "such an ambiguity in your model and potentially notify users about\n",
    "such unclear instances?\n",
    "\n",
    "• How does your model come to a specific conclusion, what about model\n",
    "interpretability?\n",
    "\n",
    "• Think beyond the pure sentiment analysis of sentences, e.g. how would\n",
    "you automatically extract relevant sentences from EPARs and ensure\n",
    "that the analysis is only applied to specific sections? It is worth to\n",
    "explore some EPARs on the EMA we"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "F-MWeYX_SPsH",
    "outputId": "77346d91-b72f-4038-e580-d8087115098c"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "266\n"
     ]
    }
   ],
   "source": [
    "print(len(data)) # 266 Rows of data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "c2LY74xVSI7k",
    "outputId": "d3d2196f-29ea-4ad6-9fe2-ed5f0a1d094a"
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1    160\n",
       "0    106\n",
       "Name: Positive, dtype: int64"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Classes\n",
    "data[\"Positive\"].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "sDVOd9dSTNrr",
    "outputId": "13644301-6b68-466f-d2f7-3ccf2c24464b"
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    230\n",
       "1     36\n",
       "Name: Negative, dtype: int64"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data['Negative'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "aaU_s040TTY1",
    "outputId": "b758e91f-dd2c-4381-bad4-f6b327b89d79"
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0    196\n",
       "1     70\n",
       "Name: Neutral, dtype: int64"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data['Neutral'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "id": "dvyhedC6TW9M"
   },
   "outputs": [],
   "source": [
    "pos=data[\"Positive\"].value_counts()[1]\n",
    "neg=data[\"Negative\"].value_counts()[1]\n",
    "neu= data[\"Neutral\"].value_counts()[1]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 1000
    },
    "id": "kcr23Wdc1OQ6",
    "outputId": "0979af67-9717-40d7-b952-34b50e3e6203"
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ID</th>\n",
       "      <th>Sentence</th>\n",
       "      <th>Positive</th>\n",
       "      <th>Negative</th>\n",
       "      <th>Neutral</th>\n",
       "      <th>check</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>The results in 2nd line treatment show an ORR ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>The long duration of response and high durable...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>The median OS time in the updated results exce...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Therefore, the clinical benefit in 2nd line tr...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>The data provided in 1st line, although prelim...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   ID                                           Sentence  Positive  Negative  \\\n",
       "0   1  The results in 2nd line treatment show an ORR ...         1         0   \n",
       "1   2  The long duration of response and high durable...         1         0   \n",
       "2   3  The median OS time in the updated results exce...         0         0   \n",
       "3   4  Therefore, the clinical benefit in 2nd line tr...         1         0   \n",
       "4   5  The data provided in 1st line, although prelim...         1         0   \n",
       "\n",
       "   Neutral  check  \n",
       "0        0      1  \n",
       "1        0      1  \n",
       "2        1      1  \n",
       "3        0      1  \n",
       "4        0      1  "
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Check that no overlap occurs per row by summing in across columns\n",
    "\n",
    "data[\"check\"] =data[[\"Neutral\",\"Negative\",\"Positive\"]].sum(axis=1)\n",
    "data.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "grCl3YWFAGQi"
   },
   "source": [
    "# Data Cleaning and Processing\n",
    "Perform a Null check and proceed with statistical features and other cleaning.\n",
    "Some basic NLP processes, such as stemming and polarity, also done."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "j-SeoKdhyZaB",
    "outputId": "89cf5466-d07a-42c8-8a45-c1f7ff112fef"
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "False"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data.isnull().values.any()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "id": "HDAamMW0yqqA"
   },
   "outputs": [],
   "source": [
    "#Lets combine all of the sentiments into a single polarity feature \n",
    "# Three classes here, 1,0, -1\n",
    "def convert_sentiment(row):\n",
    "    if row['Positive'] == 1:\n",
    "        val = 1\n",
    "    elif row['Negative'] ==1:\n",
    "        val=-1\n",
    "    else:\n",
    "        val=0\n",
    "    return val\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "id": "iBEFl3Wj2WA_"
   },
   "outputs": [],
   "source": [
    "data[\"sentiment\"]=data.apply(lambda row: convert_sentiment(row), axis=1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 677
    },
    "id": "RnAKC1tj29iR",
    "outputId": "339bf573-5e84-4457-eaf8-d615cb4face6"
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>ID</th>\n",
       "      <th>Sentence</th>\n",
       "      <th>Positive</th>\n",
       "      <th>Negative</th>\n",
       "      <th>Neutral</th>\n",
       "      <th>check</th>\n",
       "      <th>sentiment</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>The results in 2nd line treatment show an ORR ...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>The long duration of response and high durable...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>The median OS time in the updated results exce...</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Therefore, the clinical benefit in 2nd line tr...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>The data provided in 1st line, although prelim...</td>\n",
       "      <td>1</td>\n",
       "      <td>0</td>\n",
       "      <td>0</td>\n",
       "      <td>1</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   ID                                           Sentence  Positive  Negative  \\\n",
       "0   1  The results in 2nd line treatment show an ORR ...         1         0   \n",
       "1   2  The long duration of response and high durable...         1         0   \n",
       "2   3  The median OS time in the updated results exce...         0         0   \n",
       "3   4  Therefore, the clinical benefit in 2nd line tr...         1         0   \n",
       "4   5  The data provided in 1st line, although prelim...         1         0   \n",
       "\n",
       "   Neutral  check  sentiment  \n",
       "0        0      1          1  \n",
       "1        0      1          1  \n",
       "2        1      1          0  \n",
       "3        0      1          1  \n",
       "4        0      1          1  "
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {
    "id": "MJYccADa7cAd"
   },
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package stopwords to /home/yijie/nltk_data...\n",
      "[nltk_data]   Package stopwords is already up-to-date!\n"
     ]
    }
   ],
   "source": [
    "#Data cleaning and standardization\n",
    "from utils import processing"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {
    "id": "AZ0p8N5r_zPE"
   },
   "outputs": [],
   "source": [
    "data_processed = processing(data)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "BP_zCKjWnu6w"
   },
   "source": [
    "# Baseline with NGRAMS\n",
    "Our first baseline is  a basic lightGBM attempt, using our statistical features and vectorized features.\n",
    "LGBM is a gradient boosted tree method that is light, fast, and flexible.\n",
    "Results obtained with hyperparameter tuning GridSearchCV. Oversampling performed with SVMSMOTE\n",
    "\n",
    "Note for scoring, we utilize balanced acc and f1 to better handle the class imbalance\n",
    "#https://medium.com/analytics-vidhya/accuracy-vs-f1-score-6258237beca2\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "Tv5PQ6ac0O9c"
   },
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {
    "id": "gxBuKFUXzajl"
   },
   "outputs": [],
   "source": [
    "# Importing Libraries for the Machine Learning Model\n",
    "from xgboost import XGBClassifier\n",
    "from lightgbm import LGBMModel,LGBMClassifier, plot_importance\n",
    "from sklearn.metrics import confusion_matrix, accuracy_score,balanced_accuracy_score, f1_score, classification_report\n",
    "from sklearn.model_selection import train_test_split\n",
    "from sklearn.model_selection import KFold, StratifiedKFold, RepeatedStratifiedKFold\n",
    "from sklearn.model_selection import cross_val_score, cross_val_predict, GridSearchCV\n",
    "from sklearn.metrics import ConfusionMatrixDisplay\n",
    "from sklearn.feature_extraction.text import CountVectorizer\n",
    "from imblearn.over_sampling import SMOTE, ADASYN, BorderlineSMOTE, SVMSMOTE, RandomOverSampler\n",
    "from scipy import sparse"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "NGRAM_Target = 'clean_stem'\n",
    "features = data[[NGRAM_Target,'polarity_clean','polarity','polarity_clean_stem',  'count_word', 'count_unique_word', 'count_letters',\n",
    "                   'count_punctuations', 'count_words_upper', 'count_words_title',\n",
    "                   'count_stopwords', 'mean_word_len']]\n",
    "\n",
    "target = data['sentiment']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Perform NGRAM Modelling\n",
    "\n",
    "vect = CountVectorizer(ngram_range=(1,3)).fit(features[NGRAM_Target]) #NGram range just refers to the max consecutive words to make an engram of\n",
    "\n",
    "\n",
    "feature_names = vect.get_feature_names()\n",
    "#Fetch the respective train and test data and select just the relevant Sentence column, Implement vectorization\n",
    "\n",
    "vect_X =  vect.transform(features[NGRAM_Target])\n",
    "features= features.drop(columns=[NGRAM_Target])\n",
    "#Combine vectorized data with original data, minus the originalsentence \n",
    "X_vect = sparse.hstack([vect_X, features])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "5Bl-RelAnzXR",
    "outputId": "9444fc40-4f53-4456-d6c6-08ef6200d5b9"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The Train set size  (212, 6692)\n",
      "The Test set size  (54, 6692)\n"
     ]
    }
   ],
   "source": [
    "\n",
    "\n",
    "X_train, X_test, y_train, y_test = train_test_split(X_vect, target, test_size = 0.2, random_state = 42,stratify=target)\n",
    "print (\"The Train set size \", X_train.shape)\n",
    "print (\"The Test set size \", X_test.shape)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Introducing oversampling\n",
    "oversampling=True\n",
    "if oversampling == True:\n",
    "    ADAsm = SVMSMOTE(random_state=100)\n",
    "    X_train_smote, y_train_smote= ADAsm.fit_resample(X_train, y_train)\n",
    "    X_train_orig = X_train.copy()\n",
    "    y_train_orig = y_train.copy()\n",
    "    \n",
    "    X_train = X_train_smote.copy()\n",
    "    y_train = y_train_smote.copy()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Tune hyperparameters\n",
    "from utils import hyperparam_tune        \n",
    "    \n",
    "\n",
    "params = {\n",
    "        'learning_rate': [0.01,0.05, 0.1, 0.3,0.5],\n",
    "        'max_depth' : [-1,5,10,20],\n",
    "        'num_leaves' : [2,5,10,20,31],\n",
    "        'colsample_bytree' :  [0.1,0.5,1],\n",
    "        'n_estimators':  [25,50,100,150,200,]\n",
    "    }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "best,acc,acc_b,f1,rep,clfr = hyperparam_tune(\"lgbm\",params,X_train,y_train,X_test,y_test)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'colsample_bytree': 1,\n",
       " 'learning_rate': 0.3,\n",
       " 'max_depth': 10,\n",
       " 'n_estimators': 150,\n",
       " 'num_leaves': 20}"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "best"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.7037037037037037"
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "acc"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.6471861471861472"
      ]
     },
     "execution_count": 27,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "acc_b"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0.7084593680543536"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "f1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "              precision    recall  f1-score   support\n",
      "\n",
      "          -1       0.50      0.43      0.46         7\n",
      "           0       0.55      0.79      0.65        14\n",
      "           1       0.86      0.73      0.79        33\n",
      "\n",
      "    accuracy                           0.70        54\n",
      "   macro avg       0.64      0.65      0.63        54\n",
      "weighted avg       0.73      0.70      0.71        54\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(rep)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "scrolled": true
   },
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {
    "id": "T0f5MlusAjXx"
   },
   "outputs": [],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 854
    },
    "id": "eAPcRpXD1Gg5",
    "outputId": "1a56e95d-8084-43a5-c39a-138d5d053cb0",
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 640x480 with 2 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "predictions = clfr.predict(X_test)\n",
    "cm=confusion_matrix(y_test, predictions)\n",
    "disp = ConfusionMatrixDisplay(confusion_matrix=cm, display_labels=clfr.classes_)\n",
    "disp.plot()\n",
    "plt.tick_params(axis=u'both', which=u'both',length=0)\n",
    "plt.grid(False)\n",
    "plt.show()\n",
    "\n",
    "#Visualize Confusion Matrix"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {
    "id": "DMFjhEB0_yr3",
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<AxesSubplot:title={'center':'Feature importance'}, xlabel='Feature importance', ylabel='Features'>"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 1200x900 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "plt.rcParams['figure.figsize'] = [12, 9]\n",
    "sns.set(style = 'darkgrid', font_scale = 1.2)\n",
    "plot_importance(clfr.best_estimator_,  max_num_features=13)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "6681"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(vect.get_feature_names())\n",
    "#Note that we have 6691 columns,so 10 are statistical features the  Stacking works by LEFT + RIGHT data,\n",
    "# so we have hstack(vect, features)\n",
    "#Lets assume we start from 0, we notice that the top features (6681->6691) Are statistical features,\n",
    "# Last two are new NCountVectorizer Features"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'consid'"
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Let's replace the column vector names with their actual text entries\n",
    "\n",
    "vect.get_feature_names()[1403]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "colab": {
   "provenance": []
  },
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 1
}
